Group 1 - EVE Energy signed a procurement framework agreement with its affiliate, Smoore International, for continuous procurement of battery cells starting from January 1, 2026 [1] - Zhaoyi Information plans to issue H-shares and list on the Hong Kong Stock Exchange [1] - Fuke Environmental announced a change in its stock abbreviation to "Fuke Technology" effective November 26 [1] Group 2 - Dajia Weikang's shareholder and director terminated a share reduction plan ahead of schedule, having reduced 1% of total shares [2] - Aohong Electronics received approval from the China Securities Regulatory Commission for the issuance of convertible bonds [2] - Yingfeng Environment's controlling shareholder plans to issue exchangeable bonds not exceeding 1 billion yuan [2] Group 3 - Longshen Rongfa's subsidiary obtained a renewed drug production license covering various pharmaceutical products [4] - Xinhua News' subsidiary invested 15 million yuan in a fund with a total commitment of 221 million yuan [5] - Guang'an Aizhong appointed two new deputy general managers [6] Group 4 - Fosun Pharma's subsidiary's drug for gastric cancer treatment was included in the breakthrough therapy program by the National Medical Products Administration [7] - Nanjiao Foods reported a significant decline in October net profit due to rising raw material costs [8] - Nanfeng Co. won two nuclear power project bids totaling 928.7 million yuan [10] Group 5 - Puluo Pharmaceutical received a drug registration certificate for its Cefdinir capsules [11] - Liming Co.'s subsidiary received environmental approval for a new pesticide raw material project [12] - Longhua New Materials' expansion project for polyether polyols has commenced trial production [13] Group 6 - Pumen Technology's products received IVDR CE certification from TÜV Rheinland [15] - China Chemical reported new contracts worth 312.67 billion yuan from January to October [18] - China Nuclear Construction achieved new contracts totaling 123.84 billion yuan as of October [19] Group 7 - Changshu Bank's executives plan to purchase at least 550,000 shares of the bank [20] - Shandong Steel's subsidiary is applying for bankruptcy liquidation to focus on core business [21] - Huakang Clean is expected to win a bid for a purification system project worth 176 million yuan [23] Group 8 - Huawu Co. plans to internally transfer subsidiary equity [24] - Tianen Kang's subsidiary received clinical trial acceptance for a new drug [26] - Tianyi Medical's subsidiary obtained a medical device registration certificate for a blood dialysis product [27] Group 9 - Xuelang Environment is facing a pre-restructuring application from creditors [27] - Chitianhua's subsidiary resumed production after passing safety inspections [28] - Huaping Co.'s director plans to reduce 0.03% of company shares [30] Group 10 - Xizhuang Co. plans to establish a wholly-owned subsidiary in Singapore [31] - Ruisheng Intelligent's subsidiary won a 60.23 million yuan ICT project bid [32] - Junyi Digital plans to invest 120 million yuan in Guanghong Precision [33] Group 11 - Fuguang Co.'s controlling shareholder plans to increase holdings between 80 million to 150 million yuan [34] - Ganyue Express reported a 13.68% increase in logistics revenue in October [39] - Jiangsu Sop terminated its 2025 private placement plan [41] Group 12 - Langke Intelligent's shareholders plan to reduce a total of 1.68% of company shares [42] - Yuantong Express reported an 8.97% increase in express product revenue in October [45] - Jinbei Automotive plans to invest 158 million yuan to acquire 52% of Zhongtuo Technology [46]

Core Viewpoint - Tianyi Medical (301097.SZ) has received a Medical Device Registration Certificate from the National Medical Products Administration for its subsidiary Ningbo Tianyi Pharmaceutical Technology Co., Ltd, enhancing its product portfolio and competitive edge in the market [1]. Group 1: Product Registration Details - The registered product is a blood dialysis concentrate, classified as a Class III medical device, with a registration number of Guo Xie Zhu Zheng 2025310230, valid from November 13, 2025, to November 12, 2030 [2]. - The blood dialysis concentrate consists of two components: A concentrate (A liquid) and a connected dry powder (B powder), designed to meet the personalized treatment needs of patients with acute and chronic renal failure [2]. - A liquid is composed of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, acetic acid, and dialysis water, while B powder contains sodium bicarbonate, utilizing acetic acid as a buffer in a medium calcium formulation [2]. Group 2: Strategic Implications - The acquisition of the medical device registration certificate extends the company's product chain and enriches its product categories, which is beneficial for enhancing the company's overall competitiveness in the healthcare market [2].

Core Viewpoint - Tianyi Medical (301097) announced that its subsidiary, Ningbo Tianyi Pharmaceutical Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for its blood dialysis concentrate, which is intended for the treatment of acute and chronic renal failure patients undergoing hemodialysis [1] Company Summary - Tianyi Medical's subsidiary has successfully obtained regulatory approval for a new medical product, indicating progress in its product development and potential market entry [1] - The blood dialysis concentrate is specifically designed for patients with renal failure, highlighting the company's focus on addressing critical healthcare needs [1] Industry Summary - The approval of the blood dialysis concentrate aligns with the growing demand for renal care solutions, particularly in the context of increasing incidences of kidney-related diseases [1] - This development may enhance competition within the medical device sector, particularly in the field of dialysis treatment [1]

Core Viewpoint - Tianyi Medical (301097.SZ) has received a medical device registration certificate from the National Medical Products Administration for its blood dialysis concentrate, which includes A concentrate and B powder, enhancing its product offerings and competitive edge in the market [1] Group 1 - Tianyi Pharmaceutical, a subsidiary of Tianyi Medical, has obtained a medical device registration certificate for its blood dialysis concentrate [1] - The blood dialysis concentrate consists of A liquid, which includes sodium chloride, potassium chloride, calcium chloride, magnesium chloride, acetic acid, and dialysis water, and B powder, which contains sodium bicarbonate [1] - The combination of A liquid and B powder offers advantages of both types of concentrates, catering to personalized clinical treatment needs [1] Group 2 - The acquisition of the registration certificate extends the company's product chain and enriches its product categories [1] - This development is expected to enhance the overall competitiveness of the company in the medical device industry [1]

Core Viewpoint - Tianyi Medical (301097.SZ) has received a medical device registration certificate from the National Medical Products Administration for its blood dialysis concentrate product, which enhances its product line and competitiveness in the market [1] Group 1: Product Details - The registered blood dialysis concentrate consists of two components: A concentrate (A liquid) and a connected dry powder (B powder) [1] - A liquid is composed of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, acetic acid, and dialysis water, while B powder contains sodium bicarbonate [1] - This combination of A liquid and B powder leverages the advantages of both types of concentrates, catering to personalized clinical treatment needs [1] Group 2: Strategic Implications - The acquisition of the medical device registration certificate extends the company's product chain and enriches its product categories [1] - This development is expected to enhance the company's overall competitiveness in the healthcare market [1]

证券代码： 301097 证券简称：天益医疗 公告编号：2025-063 宁波天益医疗器械股份有限公司 关于公司新产品取得产品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 宁波天益医疗器械股份有限公司（以下简称"公司"）子公司宁波天益药业 科技有限公司（以下简称"天益药业"）于近日收到国家药品监督管理局颁发的 《医疗器械注册证》，具体情况如下： 一、产品注册证具体情况 | 序号 | 产品名称 | 注册证编号 | 注册 类别 | | 注册证有效期 | | | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 国械注准 | | 2025 | 年 11 13 | 月 | 日至 | 用于急、慢性肾功 | | 1 | 血液透析浓缩物 | 2025310230 | III | | | | | 能 衰竭 患者 的 血 | | | | | | 2030 | 年 11 月 | | 12 日 | | | | | 3 | | | | | | 液透析治疗。 | 二、对公司的影响 ...

Core Viewpoint - Tianyi Medical (301097) experienced a significant decline in stock price, closing at 58.24 yuan on November 19, 2025, down 5.35% from the previous day [1] Group 1: Stock Performance and Trading Data - On November 19, 2025, the trading volume was 17,500 hands, with a total transaction amount of 102 million yuan [1] - The net outflow of main funds was 2.25% of the total transaction amount, while retail investors saw a net inflow of 5.26% [1] - Over the past five days, the stock has shown fluctuating performance, with a notable drop on November 19 and a previous increase on November 18 [1][2] Group 2: Financing and Margin Trading - On November 19, 2025, the financing balance was 63.63 million yuan, with a net financing purchase of 10.18 million yuan [2] - The stock has not seen any short selling activity, with no shares sold or repaid [2] Group 3: Company Financials and Industry Comparison - For the first three quarters of 2025, Tianyi Medical reported a main revenue of 387 million yuan, a year-on-year increase of 24.14% [4] - The net profit for the same period was 20.09 million yuan, reflecting a substantial year-on-year increase of 216.81% [4] - The company’s total market capitalization is 3.418 billion yuan, significantly lower than the industry average of 11.278 billion yuan [4] - Key financial ratios indicate that Tianyi Medical has a price-to-earnings ratio of 127.57 and a gross margin of 38.39%, both of which are below industry averages [4]

Core Viewpoint - Tianyi Medical (301097) experienced a decline of 5.35% in stock price, closing at 58.24 yuan, with a total market capitalization of 3.433 billion yuan as of November 19, 2025 [1] Group 1: Stock Performance - The stock opened at 60.9 yuan, reached a high of 60.91 yuan, and a low of 57.4 yuan on the same day [1] - The trading volume was 1.02 billion yuan, with a turnover rate of 6.03% [1] Group 2: Upcoming Shareholder Meeting - Tianyi Medical will hold its third temporary shareholder meeting on December 5, 2025, at 14:00, with online voting available from 9:15 to 15:00 [1] - The record date for shareholders is December 1, 2025 [1] - Agenda items include the election of non-independent and independent directors for the fourth board, amendments to the company’s articles of association and governance systems, and the addition of expected related party transactions for 2025 [1] - Certain proposals require approval from over two-thirds of the voting rights held by attending shareholders, with related shareholders abstaining from voting on relevant proposals [1]

Core Points - Tianyi Medical announced the convening of the 27th meeting of its third board of directors on November 19, 2025, to review the election of the fourth board of directors [2] - The company nominated three candidates for non-independent directors and three candidates for independent directors, with one candidate being a professional accountant [2] - The election will be conducted using a cumulative voting system, and the company will also hold a workers' representative meeting to elect one worker representative director [2]

宁波天益医疗器械股份有限公司 独立董事候选人声明与承诺 声明人郑一峰作为宁波天益医疗器械股份有限公司第四届董事 会独立董事候选人，已充分了解并同意由提名人宁波天益医疗器械股 份有限公司董事会提名为宁波天益医疗器械股份有限公司（以下简称 该公司）第四届董事会独立董事候选人。现公开声明和保证，本人与 该公司之间不存在任何影响本人独立性的关系，且符合相关法律、行 政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董 事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、本人已经通过宁波天益医疗器械股份有限公司第三届董事会 提名委员会或者独立董事专门会议资格审查，提名人与本人不存在利 害关系或者其他可能影响独立履职情形的密切关系。 是 □ 否 如否，请详细说明： 二、本人不存在《中华人民共和国公司法》第一百七十八条等规 定不得担任公司董事的情形。 是 □ 否 如否，请详细说明： 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳 证券交易所业务规则规定的独立董事任职资格和条件。 是 □ 否 如否，请详细说明： 四、本人符合该公司章程规定的独立董事任职条件。 是 □ 否 如否，请详细说明： 五、本 ...